quinacrine has been researched along with fluconazole in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gabriel, I; Paluszkiewicz, E; Rząd, K | 1 |
| Bernardo, SM; Chavez-Dozal, A; Jahng, M; Kulkarny, VV; Lee, SA; Parra, KJ; Rane, HS | 1 |
6 other study(ies) available for quinacrine and fluconazole
| Article | Year |
|---|---|
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance.
Topics: Aminacrine; Antifungal Agents; Candida albicans; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fluconazole; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Quinacrine inhibits Candida albicans growth and filamentation at neutral pH.
Topics: Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Biofilms; Candida albicans; Caspofungin; Drug Combinations; Drug Repositioning; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Endocytosis; Fluconazole; Hydrogen-Ion Concentration; Hyphae; Lipopeptides; Microbial Sensitivity Tests; Microbial Viability; Plankton; Quinacrine | 2014 |